Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.83 |
| ▸ | APP | P05067 | 3/20 | 0.64 |
| ▸ | BACE2 | Q9Y5Z0 | 7/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | KCNH1 | O95259 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2154153 | 0.99 | BACE1 (0.82) | BACE1APPBACE2CYP3A4CYP2D6 | |
| SCHEMBL246740 | 0.91 | BACE1 (1.00) | BACE1APPBACE2CYP3A4 | |
| SCHEMBL14876637 | 0.91 | BACE1 (1.00) | BACE1APPBACE2CYP3A4 | |
| SCHEMBL14876661 | 0.91 | BACE1 (1.00) | BACE1APPBACE2CYP3A4 | |
| SCHEMBL2154072 | 0.89 | BACE1 (0.66) | BACE1APPBACE2CYP3A4CYP2D6 | |
| SCHEMBL2153892 | 0.89 | BACE1 (0.66) | BACE1APPBACE2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL2154301 | 0.88 | BACE1 (0.65) | BACE1APPBACE2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL2154078 | 0.88 | BACE1 (0.65) | BACE1APPBACE2CYP3A4CYP2D6 | |
| SCHEMBL6900593 | 0.88 | BACE1 (0.65) | BACE1APPBACE2CYP3A4CYP2D6 | |
| SCHEMBL2154111 | 0.88 | BACE1 (0.65) | BACE1APPBACE2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011080176-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-07-07 | — | — | WO | claimed |
| US-20150322038-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| EP-2519515-B1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-20120277244-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2012-11-01 | — | — | US | disclosed |
| WO-2011080176-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011080176-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128385-A1 | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | BACE2, BACE1, IAPP | BACE1 2/4885APP 5/4885BACE2 1/4885 |
| US-20150322038-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIK5, GRIN2C, GRIN2A | BACE1 436/4885APP 49/4885BACE2 736/4885 |
| US-20120277244-A1 | PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS | GRIK5, GRIN2C, GRIN2A | BACE1 353/4885APP 59/4885BACE2 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.